New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
14:31 EDTAKRXAkorn sees FY13 adjusted EPS 57c-61c, consensus 66c
Sees FY13 revenue $325M-$335M, consensus $330.73M. The company's guidance excludes the impact from any products for which the company has not yet received FDA approval.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
10:23 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:11 EDTAKRXAkorn initiated with Outperform, $50 target at William Blair
William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.
December 8, 2014
11:30 EDTAKRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use